

**From:** [SANTE INFO](#)  
**To:** [REDACTED]@gmail.com  
**Subject:** FW: EU covid therapeutics strategy  
**Date:** vendredi 2 juillet 2021 16:05:00

---

Dear [REDACTED],

Thank you for your interest in the EU strategy for Covid-19 therapeutics.

The aim of this strategy is to put in place a mechanism to speed up the entire process of development of therapeutics (encompassing clinical research and clinical trials, the manufacturing, the purchase and the availability of the products in the EU). The majority of the actions planned in the strategy are now at an early stage of implementation and they will be gradually defined in the near future. Some actions have however been completed or are planned shortly.

- Identification of the 5 most promising therapeutics and establishing of a broader portfolio of 10 potential therapeutics: on 29 June the EC revealed the list of 5 therapeutics that are in an advanced stage of development

The list is based on objective criteria, namely the rolling review evaluation by the European Medicines Agency (EMA).

For more information on the list, please check Commission identifies five promising candidate therapeutics (europa.eu) or the press release .

The therapeutics in the list are already under evaluation by EMA. A rolling review is a regulatory tool that EMA uses to speed up the assessment of a promising medicinal products during a public health emergency. EMA includes products in the rolling review procedure based on promising preliminary results from clinical studies.

The Commission is also working on a framework for a broader and diverse portfolio of therapeutics with the help of the newly established expert group on variants. The selection process will be objective and science based and the selection criteria will be also agreed with the Member States.

- EU matchmaking event for COVID19 therapeutics industrial production: the event is planned on the 12th and 13th of July 2021. The participation in the matchmaking event is open to a range of organisations and pharmaceutical companies. The event aims at supporting the acceleration of the development and upscale of Covid-19 therapeutics production, enhancing the participation of EU companies in the Covid-19 therapeutics value chains, speed up connection between organisations and help in retro-planning strategy for production. For more information please check the link to the matchmaking platform: European Matchmaking event - Development and production of COVID-19 therapeutics - Info (b2match.io).

A preparatory webinar took place on the 14th of June 2021. The webinar was recorded and uploaded in the matchmaking platform.

Kind regards,  
SANTE INFO

-----Original Message-----

From: [REDACTED]@ec.europa.eu>  
Sent: Wednesday, June 23, 2021 10:59 AM  
To: [REDACTED]@gmail.com>  
Cc: SANTE INFO <xxxxxxxxxx@xx.xxxxxx.xx>  
Subject: RE: EU covid therapeutics strategy

Dear [REDACTED]

Many thanks for your interest.

At the spokespersons' service, we only handle media and press requests. I therefore copy in my colleagues from Directorate-General SANTE who are better placed to get back to you.

Have a nice day and best regards

[REDACTED]

[REDACTED]

health, food safety and transport

European Commission  
Spokespersons' Service

BERL [REDACTED]  
B-1049 Brussels/Belgium  
+32 2 298 46 80  
+32 460 764680  
[REDACTED]@ec.europa.eu

<https://ec.europa.eu/commission/presscorner/home/en>

#vdlCommission

\* The information contained in this mail cannot be quoted in my name \*

-----Original Message-----

From: [REDACTED]@gmail.com>  
Sent: Wednesday, June 23, 2021 10:46 AM  
To: [REDACTED]@ec.europa.eu>  
Subject: EU covid therapeutics strategy

Dear [REDACTED]

I am following with interest this excellent strategy on covid therapeutics. Please can you tell me when more details will be shared?

Many thanks  
[REDACTED]